Literature DB >> 29684468

Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease.

Qinwei Yu1, Zhenzhou Jiang2, Luyong Zhang3.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive fat deposition in the liver in the absence of significant alcohol consumption. Dysregulated bile acid (BA) metabolism is an important indicator in the pathology of NAFLD, which could progress into more severe forms of liver injury. Lipid metabolism, immune environment and intestinal bacteria are all affected by dysregulated BA metabolism directly, but the mechanisms remain unclear. Several drug candidates that target BA metabolism, either used alone or in combination with other agents, are currently under development for treatment of NAFLD. Here, we summarize the relationship of dysregulated BA metabolism and NAFLD, discuss the effects and mechanisms of dysregulated BAs-induced lipid metabolism disorder. Challenges in developing novel treatments are also discussed.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BA-activated receptor; Bile acids; Inflammation; Lipid metabolism; Non-alcoholic fatty liver disease

Mesh:

Substances:

Year:  2018        PMID: 29684468     DOI: 10.1016/j.pharmthera.2018.04.005

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  11 in total

Review 1.  Role and effective therapeutic target of gut microbiota in NAFLD/NASH.

Authors:  Qun Liu; Shousheng Liu; Lizhen Chen; Zhenzhen Zhao; Shuixian Du; Quanjiang Dong; Yongning Xin; Shiying Xuan
Journal:  Exp Ther Med       Date:  2019-07-17       Impact factor: 2.447

Review 2.  The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease.

Authors:  Yiming Ni; Mengna Lu; Yuan Xu; Qixue Wang; Xinyi Gu; Ying Li; Tongxi Zhuang; Chenyi Xia; Ting Zhang; Xiao-Jun Gou; Mingmei Zhou
Journal:  Front Microbiol       Date:  2022-06-27       Impact factor: 6.064

Review 3.  Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease.

Authors:  Ludovico Abenavoli; Tetyana Falalyeyeva; Luigi Boccuto; Olena Tsyryuk; Nazarii Kobyliak
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-11

4.  Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism.

Authors:  Songsong Wang; Feiya Sheng; Liang Zou; Jianbo Xiao; Peng Li
Journal:  J Adv Res       Date:  2021-06-08       Impact factor: 10.479

5.  Circulating bile acids concentration is predictive of coronary artery disease in human.

Authors:  Caroline Chong Nguyen; Denis Duboc; Dominique Rainteau; Harry Sokol; Lydie Humbert; Philippe Seksik; Adèle Bellino; Hendy Abdoul; Naïm Bouazza; Jean-Marc Treluyer; Malika Saadi; Karim Wahbi; Heithem Soliman; Benoit Coffin; André Bado; Maude Le Gall; Olivier Varenne; Henri Duboc
Journal:  Sci Rep       Date:  2021-11-22       Impact factor: 4.379

Review 6.  The role of the microbiome in NAFLD and NASH.

Authors:  Aleksandra A Kolodziejczyk; Danping Zheng; Oren Shibolet; Eran Elinav
Journal:  EMBO Mol Med       Date:  2019-02       Impact factor: 12.137

7.  Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis.

Authors:  Hongshan Li; Yingfei Xi; Xin Xin; Huajie Tian; Yiyang Hu
Journal:  Nutr Metab (Lond)       Date:  2020-05-01       Impact factor: 4.169

8.  The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study.

Authors:  Boyu Li; Yanjin Hu; Guang Wang; Lihong Liu
Journal:  BMC Pharmacol Toxicol       Date:  2020-06-15       Impact factor: 2.483

Review 9.  Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression.

Authors:  Aline Gottlieb; Ali Canbay
Journal:  Cells       Date:  2019-10-30       Impact factor: 6.600

Review 10.  Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms.

Authors:  Ashok Mandala; Rachel C Janssen; Sirish Palle; Kevin R Short; Jacob E Friedman
Journal:  Nutrients       Date:  2020-10-16       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.